1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch

VectorBuilder

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2014

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Established in 2014 and based in Guangzhou, China, VectorBuilder operates as a scientific research customized carrier supplier that provides gene delivery solutions. Bruce Lahn is the founder and chief scientist of professorship at the University of Chicago and the researcher at the Howard Hughes Medical Institute (HHMI). In February 2022, Pall Corporation has become the strategic partner of VectorBuilder. In July 2022, it invested USD 30 million to build AAV superbank. In March 2023, VectorBuilder raised series C+ funding from returning investor Yuexiu Industrial Investment Funds Management. The round was part of a larger CNY 410 million series C funding. In May 2023, the firm raised strategic investment. The strategic investment values the company at CNY 7 billion post-money. The company provides gene delivery solutions, including virus packaging, protein expression and in vitro transcription. The business of the company includes customized services of scientific research carrier, CRO service, CDMO service and property right export business. CDMO service includes plasmid DNA, viral vector and mRNA. Its products include shRNA libraries, dual-gRNA CRISPR libraries, EGFP and HiExpress™, luciferase IVT mRNA and AAV virus-like particles (VLPs). VectorBuilder's carrier systems include lentivirus, adenovirus, AAV, HSV and VSV. In 2022, the company's operating income was CNY 281 million, of which the net profit was CNY 50.73 million.
Current Investors
Legend Capital, Yuexiu Industrial Investment Funds Management, Xiamen C&D Emerging Industry Equity Investment

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
BPO Services, Molecular Science, Genetics & Gene Therapy
Website
www.vectorbuilder.cn
Company Stage
Series C
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.